Platelet derived growth factor receptor beta. Every medicine in our data that ChEMBL or the Guide to Pharmacology records as acting on this protein, with the source for each and its current clinical trials on this site.
| Medicine | How it acts | Source | Current trials here |
|---|---|---|---|
| Anlotinib CHEMBL4303201 |
Platelet-derived growth factor receptor beta inhibitor Inhibitor Small molecule |
ChEMBL only | 76 |
| Regorafenib CHEMBL1946170 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 43 |
| Imatinib CHEMBL941 |
Platelet-derived growth factor receptor beta inhibitor Inhibitor Small molecule |
ChEMBL only | 33 |
| Sunitinib CHEMBL535 |
Platelet-derived growth factor receptor inhibitor Inhibitor Platelet-derived growth factor receptor beta inhibitor Inhibitor Small molecule |
✓ Both | 21 |
| Sorafenib CHEMBL1336 |
Platelet-derived growth factor receptor beta inhibitor Inhibitor Small molecule |
✓ Both | 15 |
| Famitinib CHEMBL1278146 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 11 |
| Cediranib Maleate CHEMBL2103798 |
Inhibits PDGFRB Primary target Small molecule |
Guide to Pharmacology only | 10 |
| Pazopanib CHEMBL477772 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 10 |
| Nintedanib CHEMBL502835 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 7 |
| Quizartinib CHEMBL576982 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 7 |
| Midostaurin CHEMBL608533 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 5 |
| Sunitinib Malate CHEMBL1567 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
ChEMBL only | 3 |
| Masitinib CHEMBL1908391 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 2 |
| Seralutinib CHEMBL4650333 |
Platelet-derived growth factor receptor inhibitor Inhibitor Small molecule |
✓ Both | 2 |
| Tivozanib CHEMBL1289494 |
Platelet-derived growth factor receptor beta inhibitor Inhibitor Small molecule |
ChEMBL only | 2 |
“Both” means ChEMBL and the Guide to Pharmacology each record this medicine acting on this protein; “only” means one source records it and the other does not (often because it lists fewer secondary targets). The Guide to Pharmacology adds a medicine here only when this protein is its primary target. Medicines without a link have no page on this site yet.
| Disease | Medicines tested | Furthest trial phase |
|---|---|---|
| Acute myeloid leukemia | 6 | Phase 3 |
| Breast cancer | 6 | Phase 3 |
| Colorectal cancer | 6 | Phase 3 |
| Non-small cell lung carcinoma | 6 | Phase 3 |
| Hepatocellular carcinoma | 5 | Phase 3 |
| Acute lymphoblastic leukemia | 4 | Phase 3 |
| Cervical cancer | 4 | Phase 3 |
| Fallopian tube cancer | 4 | Phase 3 |
| Ovarian cancer | 4 | Phase 3 |
| Primary peritoneal carcinoma | 4 | Phase 3 |
| Glioblastoma | 4 | Phase 2/3 |
| Age-related macular degeneration | 4 | Phase 2 |
| Exocrine pancreatic carcinoma | 3 | Phase 3 |
| Gastrointestinal stromal tumor | 3 | Phase 3 |
| Kidney cancer | 3 | Phase 3 |
From ChEMBL's drug-disease records, which draw on trial registries. A trial phase is not an approval; approved uses are on each medicine's page from the regulators' own records.
Which medicines act on this protein comes from two independent, expert-curated sources: ChEMBL's mechanism-of-action records (via the Open Targets Platform) and the IUPHAR/BPS Guide to PHARMACOLOGY. Each row says which of them lists it. Data from them is shared here under their share-alike licences (CC BY-SA 3.0 and 4.0).
A job re-reads both sources every 30 days. Medicines are matched to our pages by exact name or a ChEMBL-curated synonym, and to the Guide to Pharmacology by ChEMBL ID or exact name, never by a close spelling. No AI drafting. See our methodology. The Open Targets data on this page was last retrieved on 30 Sep 2026. How every register is built: methodology · fixes we have made: corrections log.
